Continuous Glucose Monitoring for Diabetes

This trial aims to help people with type 2 or steroid-induced diabetes manage their blood sugar levels after hospital discharge. It compares two groups: one using the Libre 3 Plus continuous glucose monitor, which displays real-time blood sugar levels, and another using a hidden monitor (blinded continuous glucose monitoring) that requires fingerstick tests. The researchers aim to determine which method better aids diabetes management. This study may suit individuals who have been hospitalized for diabetes treatment and plan to use insulin at home. Participants will wear a sensor for 28 days and have telehealth check-ins. As an unphased trial, this study offers a unique opportunity to explore innovative diabetes management strategies and contribute to valuable research.

The trial information does not specify whether you need to stop taking your current medications. It seems likely that you can continue your current medications, as the focus is on monitoring glucose levels with different devices.

Research has shown that the Libre 3 Plus continuous glucose monitoring (CGM) system presents some safety concerns. Reports have indicated incorrect glucose readings, and some sensors required replacement. Abbott, the device manufacturer, issued a recall due to these problems. They reported 860 serious injuries and seven deaths related to these issues. Despite these concerns, most users generally consider the Libre sensors safe and effective.

Researchers are excited about the trial of the Libre 3 Plus continuous glucose monitoring (CGM) system because it offers a new approach to managing diabetes. Unlike traditional methods that rely on frequent fingerstick blood tests, this system provides real-time, continuous glucose readings without the need for manual checks. The unmasked monitoring allows users to see their glucose levels in real-time, potentially leading to better management of their condition and improved quality of life. Additionally, the trial compares this system with a blinded CGM combined with fingerstick monitoring, which could highlight the advantages of continuous, visible data in diabetes care.

Research has shown that the Libre 3 Plus continuous glucose monitoring (CGM) system, one of the treatments tested in this trial, can significantly aid in diabetes management. Studies indicate that using the Libre CGM system can lower A1C levels, a crucial measure of blood sugar control. Specifically, evidence shows a 0.9% reduction in A1C within 3 to 6 months for insulin users. The system provides real-time glucose readings, enabling users to make better decisions about managing their diabetes. Additionally, the Libre 3 CGM demonstrates high accuracy, with about 97-98% of its results closely matching lab standards, even when blood sugar is low. Another arm of this trial involves using Blinded Continuous Glucose Monitoring alongside fingerstick monitoring as an active comparator.⁶⁷⁸⁹¹⁰